Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Cretostimogene in Non-muscle invasive bladder cancer, Cancer. The expected timing is based on the latest available company guidance and may change.
CORE-008 trial. 10/2024 - Cohort A trial initiated. 3/2025- Cohort B initiated. 5/13/25- Initiated Cohort CX. 8/7/25- Topline data for cohort CX in H1 2026. 11/25/25- Present cohort A first results at SUO'25 on December 5, 2025. 02/27/26:- CORE-008 Cohort A SUO data showed 88% CR. Cohort CX first Phase 2 results expected H1 2026. 05/08/26:- Cohort CX first results at AUA May 16, 2026; Cohort A durability data expected during 2026. 05/15/26:- CORE-008 Cohort CX first results showed high HG-EFS and CR. Durability data expected H2 2026. 08/06/26:- CORE-008 durability data remain expected in 2026.
Verification
Confirm timing and program details against the company announcement or filing.